



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.: RU-0223

Inventors: Minko et al.

Serial No.: 10/780,137

Filing Date: February 17, 2004


Examiner: Not Yet Assigned

Group Art Unit: 1642

Title: Complex Drug Delivery Composition and
Method for Treating Cancer

I, Jane Massey Licata, Registration No. 32,257,
certify that this correspondence is being deposited
with the U.S. Postal Service as First Class mail in
an envelope addressed to the Commissioner for Patents
P.O. Box 1450, Alexandria, VA 22313-1450

On this date: April 19, 2004


Jane Massey Licata, Registration No. 32,257

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

(XX) In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified

application, within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, no additional fee is required.

() In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, therefore:

() Certification in Accordance with §1.97(e) is attached hereto; or

() Authorization to charge Deposit Account No. 50-1616 the fee of \$180.00 as set forth in §1.17(p) is provided.

() In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee, therefore included are: Certification in Accordance with §1.97(e); Petition Requesting Consideration of the Information Disclosure Statement; and the fee of \$130.00 as set forth in §1.17(I) (1).

(XX) Copies of each of the references listed on the attached Form PTO-1449 (modified) are enclosed herewith.

() In accordance with §1.98(d), copies of some or all of the references listed on the attached Form PTO-1449 (modified) are not enclosed herewith because they were previously submitted to the U.S. Patent and Trademark Office in prior application Serial No. _____, filed _____, for which a claim for priority under 35 U.S.C. §120 has been made in the instant application.

Please charge any deficiency or credit any overpayment to Deposit Account No. 50-1619. This form is submitted in duplicate.

() The relevance of the listed references in a foreign language is as stated in the specification at pages @@.

(XX) All listed references are in the English language.

Respectfully submitted,



Jane Massey Licata
Registration No. 32,257

Date: April 19, 2004

Licata & Tyrrell P.C.
66 E. Main Street
Marlton, New Jersey 08053

(856) 810-1515



Form PTO-1449 Modified List of Patents and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce	Docket No. RU-0223	Serial No. 10/780,137
	Applicant Minko et al.	
	Filing Date February 17, 2004	Group 1642

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AA	DiPaola et al., "Targeting Apoptosis in Prostate Cancer", Hematol. Oncol. Clin. North Am. 2001 15:509-524
AB	Conover et al., "Camptothecin Delivery Systems:The Antitumor Activity of a Camptothecin-20-0-Polyethethylene Glycol Ester Transport Form", Anticancer Res. 1997 17:3361-3368
AC	Kopecek et al., "HPMA copolymer-anticancer drug conjugates:design, activity, and mechanism of action", Eur. J. Pharm. Biopharm 2000 50:61-81
AD	Kopecek et al., "Water soluble polymers in tumor targeted delivery", J. Controlled Rel. 2001 74:147-158
AE	Michaelis et al., "Coupling of the antitumoral enzyme bovine seminal ribonuclease to polyethylene glycol chains increases its systemic efficacy in mice"Anticancer Drugs 2002 13:149-154
AF	Minko et al., "Efficacy of the Chemotherapeutic Action of HPMA Copolymer-Bound in Doxrubicin in a Solid Tumor Model of Ovarian Carcinoma", Int. J. Cancer 2000 86:108-117
AG	Minko et al., "HPMA copolymer bound adriamycin overcomes MDR1 gene encoded resistance in a human ovarian carcinoma cell line", J. Controlled Rel. 1998 54:223-233
AH	Minko et al., "Chronic exposure to HPMA copolymer-bound adriamycin does not induce multidrug resistance in a human ovarian carcinoma cell lines", J. Controlled Rel. 1999 59:133-148
AI	Minko et al., "The Influence Cytotoxicity of Macromolecules and of VEGF Gene Modulated Vascular Permeability on the Enhanced Permeability and Retention Effect in Resistant Solid Tumors", Pharm. Res. 2000 17:505-514

EXAMINER	DATE CONSIDERED
-----------------	------------------------

Form PTO-1449 Modified List of Patents and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce		Docket No. RU-0223	Serial No. 10/780,137
		Applicant Minko et al.	
		Filing Date February 17, 2004	Group 1642
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	AJ	Minko et al., "Enhancing the anticancer efficacy of camptothecin using biotinylated poly(ethyleneglycol) conjugates in sensitive and multidrug-resistant human ovarian carcinoma cells", Cancer Chemother Pharmacol. 2002 50:143-150	
	AK	Minko et al., "Comparison of the Anticancer Effect of Free and HPMA Copolymer-Bound Adriamycin in Human Ovarian Carcinoma Cells", Pharm. Res. 1999 16(7):986-996	
	AL	Minko et al., "Preliminary evaluation of caspases-dependent apoptosis signaling pathways of free and HPMA copolymer-bound doxorubicin in human ovarian carcinoma cells", J. Control. Rel. 2001 71:227-237	
	AM	Minko et al., "Advanced Drug Delivery Systems in Cancer Chemotherapy", Disease Management and Clinical Outcomes 2001 3:48-54	
EXAMINER		DATE CONSIDERED	

Form PTO-1449 Modified List of Patents and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce	Docket No. RU-0223	Serial No. 10/780,137
	Applicant Minko et al.	
	Filing Date February 17, 2004	Group 1642

U. S. PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Name	Class	Subclass
	BA	6,258,774	7-10-01	Stein et al.	514	2

FOREIGN PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Country	Translation YES NO	
	BB	WO 97/19954	5-6-97	PCT	x	

EXAMINER

DATE CONSIDERED